The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Toxicologist and Pace® Regulatory Expert Sherry Sachdeva to discuss industry updates & impacts MINNEAPOLIS, MINNESOTA / ACCESS Newswire / March 10, 2026 / The European Union has expanded how endocrine ...

Psychiatric diagnosis still relies on symptom checklists that were never designed to reflect biology. A peer-reviewed invited review published in Brain Medicine now synthesizes recent advances across ...